Japan, April 14 -- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,INST NATL DE LA SANTE & DE LA RECHERCHE MEDICAL,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS,UNIVERSITE DE PARIS has got intellectual property rights for 'BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS - CLOVaS SYNDROME).' Other related details are as follows:
Application Number: JP,2022-012963
Category (FI): A61P9/14,A61P35/00,A61K31/4439,A61P19/00
Stage: Grant (IP right granted following substantive examination.)
Filing Date: Jan. 31, 2022
Publication Date: April 12, 2022
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication....